Ranbaxy Labs Q4 PAT seen up 23% at Rs 323 cr
Pharma major Ranbaxy Labs is set to announce its results for the quarter ended December 2010. According to CNBC-TV18 estimates, its profit after tax (PAT) is expected to go up by 23% to Rs 323 crore in Q4CY10 as against Rs 262 crore in same quarter the previous year.
February 22, 2011 / 14:15 IST
Pharma major Ranbaxy Labs is set to announce its results for the quarter ended December 2010. According to CNBC-TV18 estimates, its profit after tax (PAT) is expected to go up by 23% to Rs 323 crore in Q4CY10 as against Rs 262 crore in same quarter the previous year.
Revenues are seen going up by 2% to Rs 2,303 crore from Rs 2,255 crore. Operating profit margin too is seen improving at 20% versus 16.3% (YoY).EBITDA is expected to go up at Rs 458 crore as against Rs 368 crore on year-on-year basis.Watch out for: -Revenue boost due to Aricept Generic; but YoY growth flat due to Valtrex generic exclusivity in Q4CY09 hence high base effect (Q4CY09 saw US grow 70% to Rs 833 crore & Q3 growth was 70% due to Valtrex generic)
-Aricept Generic is a USD 2 billion drug, Eisai Pharma is the innovator used for alzhiemers
-Ranbaxy launched with 180 exclusivity in November 26 2010 so full affect will be seen in Q1CY11
-Expected to garner sales of USD 240 million & profit of USD 168 million with EPS contribution of Rs 17
-Core growth from domestic business due to Project Viraat
-Domestic business + 18% in Q2
-Margins to be boosted due to Aricept Generic Launch
-One offs are not accounted for so watch for forex/extraordinaires
-Commentary on CY11 Guidance
-Commentary on Lipitor Launch, Management Rejig, USFDA issues, Other FTF and site transfers Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
